Case Report

Systemic Lupus Erythematosus Presenting as Myopericarditis with Acute Heart Failure: A Case Report and Literature Review

Richard Jesse Durrance,1 Malahat Movahedian,1 Worku Haile,1 Katerina Teller,2 and Richard Pinsker1

1Department of Medicine, Jamaica Hospital Medical Center, 8900 Van Wyck Expressway, Jamaica, NY 11418, USA
2Department of Rheumatology, Jamaica Hospital Medical Center, 8900 Van Wyck Expressway, Jamaica, NY 11418, USA

Correspondence should be addressed to Richard Jesse Durrance; jessedurrance@gmail.com

Received 15 April 2019; Revised 7 July 2019; Accepted 14 July 2019; Published 24 July 2019

Acute heart failure, defined as the rapid change in signs and symptoms of right or left ventricular overload requiring urgent medical management, accounts for more than one million hospitalizations per year [1]. While the vast majority are secondary to known chronic heart failure or coronary artery disease, the patient that defies both these categories provides a diagnostic challenge, which carries significant therapeutic and prognostic consequences.

Systemic lupus erythematosus (SLE), a multi-system autoimmune disorder affecting an estimated 300,000 people in the United States [1], typically presents with compromise of joints, skin, or the kidneys [2]. The cardiovascular implications of the disease have been well described, with both specific cardiac tissue involvement and a predisposition to atherosclerotic disease [3, 4]. Cardiac involvement has been reported to be present in greater than 50% of patients [5–7] and can affect any of the three layers of the cardiac tissue: endocardium, myocardium, or epicardium, as well as the pericardial serosa. However, while prevalence of cardiac involvement is elevated, the prevalence of dilated cardiomyopathy in SLE is not known. In addition, while post-mortem studies have found prevalence of myocarditis greater than 50%, clinically significant myocarditis has been reported in approximately 9% of patients [7].
The autoantibody profile of cardiac involvement has been postulated, with suggested specificity for the cardiac tissue described: endocardial and valvular pathology has demonstrated association with the presence of anti-phospholipid and anti-cardiolipin antibodies [8], whereas myocarditis has been associated with anti-Ro antibodies; pericarditis, while seldom symptomatic, has not shown a particular autoantibody profile [5].

Given that the identification of SLE can be elusive and is often significantly delayed [9], and the etiologic diagnosis of heart failure is an important determinant in therapeutic management, the combination of SLE presenting with acute heart failure due to dilated cardiomyopathy presents a unique and only anecdotally recognized occurrence in the literature to date. However, while limited case reports and case series at tertiary care centers exist, a comprehensive compilation and review of these anecdotal cases has not, to our knowledge, been done. Therefore, we present the case of a middle-aged woman with no significant past medical history and no underlying etiology. While the syndromic diagnosis of dilated cardiomyopathy was made, the etiology remained unknown.

### 2. Case Presentation

A 49-year-old Jamaican female with insignificant past medical history presented to the Emergency Department of an urban hospital with a chief complaint of progressively worsening shortness of breath of approximately 4 weeks evolution. Physical exam was remarkable for marked jugular venous distension, bilateral basal wet crackles, a distended and globally tender abdomen with positive fluid shift and positive hepatogigular reflex, as well as bilateral +2 lower leg edema. The patient’s labs are shown in Table 1 and were remarkable for anemia, elevated troponin, markedly elevated pro-BNP, transaminases, mildly elevated TSH, and CRP. ECG tracing showed atrial flutter with a ventricular rate of 126 bpm (Figure 1). Chest X-ray showed a markedly enlarged cardiac silhouette with a water-bottle appearance suspicious for pericardial effusion (Figure 2), for which an echocardiogram was done on hospital day 1, and confirmed the presence of a significantly dilated right ventricle, severe tricuspid, and moderate mitral regurgitation with no valvular structural abnormalities described. In addition, a moderately compromised left ventricular ejection fraction (LVEF) (30–40%) and a large pericardial effusion (Figure 3) were shown. CT of the chest with pulmonary artery protocol was not supportive of pulmonary embolism as the underlying etiology. While the syndromic diagnosis of dilated cardiomyopathy with right sided heart failure was made, the etiology remained unknown.

The patient was started on beta-blocker and diuretic therapy, and with close monitoring began to improve from her heart failure. While aggressive medical management continued, an etiologic search for the underlying pathology began. Toxicology and infectious disease markers were negative. A viral panel was sent out, and later returned as unremarkable. A search for underlying malignancy also was negative. Left heart catheterization showed normal coronaries but was remarkable for severe mitral and tricuspid regurgitation. Right heart catheterization was performed due to the patient’s persistently labile hemodynamics intermittently requiring pressor support suggestive of cardiogenic shock due to right heart failure and to establish an initial baseline of pulmonary artery pressure in newly diagnosed heart failure without clear etiology.

This revealed severe mitral and tricuspid regurgitation with moderate pulmonary regurgitation and only mildly increased pulmonary artery pressure, thereby supporting the mechanism

| Laboratory study       | Patient   | Reference range |
|------------------------|-----------|-----------------|
| Hemoglobin             | 9.3*      | 12–16 g/dL      |
| Hematocrit             | 29.8*     | 36–47%          |
| WBC                    | 6.4       | 4.0–10×10^9/L   |
| Platelets              | 315       | 150–450×10^9/L  |
| INR                    | 1.4*      | <1.4            |
| ESR                    | 18        | 0–20 mm/hr      |
| C-reactive protein     | 2.9*      | 0–0.8 mg/dL     |
| Creatinine             | 1.3       | 0.7–1.3 mg/dL   |
| BUN                    | 42*       | 8–20 mg/dL      |
| ALT                    | 800*      | 0–35 U/L        |
| AST                    | 1074*     | 0–35 U/L        |
| Protein                | 8.5*      | 6.0–7.8 g/dL    |
| Albumin                | 3.5       | 3.5–5.5 g/dL    |
| Troponin               | 0.237*    | 0–0.1 ng/mL     |
| Pro-BNP                | 15600*    | <400 pg/mL      |
| TSH                    | 5.04*     | 0.5–5.0 mU/L    |
| Free T4                | 1.83      | 0.9–2.4 ng/dL   |
| Free T3                | 2.09*     | 3.6–5.6 ng/dL   |
| ANA                    | 1:1280*   | <1:40           |
| Anti-ds-DNA            | 7         | <30 IU/mL       |
| Anti-Smith             | 8 Al*     | Negative        |
| Complement C3          | 70        | 88–201 mg/dL    |
| Complement C4          | 13.1      | 15–45 mg/dL     |
| Beta-2 glycoprotein    | Negative  | Negative        |
| Anti-cardiolipin       | Negative  | Negative        |
| Lyme serology          | Negative  | Negative        |
| TB quantiferon         | Negative  | Negative        |
| HIV                    | Negative  | Negative        |

WBC: white blood cell count; INR: international normalized ratio; ESR: erythrocyte sedimentation rate; BUN: blood urea nitrogen; ALT: alanine aminotransferase; AST: aspartate aminotransferase; pro-BNP: B-type natriuretic peptide; TSH: thyroid-stimulating hormone; ANA: anti-nuclear antibody titer; anti-ds-DNA: anti-double-stranded DNA. * denotes significant clinical finding.

![Figure 1: ECG of the patient on admission showing atrial flutter with a ventricular rate of 126 beats/minute and T wave inversions in inferior and lateral leads.](image-url)
of decompensated heart failure as secondary to dilated cardiomyopathy.

It was only when ANA titers came back strongly positive with low C3 and C4 complement levels that the etiology was suspected to be most likely autoimmune. The patient was immediately started on prednisone (40 mg daily), and further workup showed elevated levels of both anti-double-stranded DNA and anti-Smith antibodies along with decreased levels of C3 and C4, confirming a diagnosis of SLE and lupus myocarditis. On further examination of the patient, no other clinical findings of Lupus could be identified besides microcytic-hypochromic anemia.

On subsequent follow-up, the patient showed continuous improvement with steroid therapy and was ultimately scheduled for valve replacement surgery. As heart function monitoring and prednisone therapy continued, surgical
intervention was ultimately averted. The patient progressed with complete functional recovery. A year later, EKG showed a normal sinus rhythm; ECHO analysis showed a LVEF of 55%; and the patient remained clinically stable on maintenance hydroxychloroquine and prednisone therapy, avoiding surgical intervention.

3. Literature Review

A comprehensive literature review of case reports and case series in which dilated cardiomyopathy was associated with the presentation of SLE was performed. Literature searches were conducted in PubMed and Google Scholar. Keyword and MeSH searches included the following: lupus, SLE, systemic lupus erythematosus, dilated cardiomyopathy, and heart failure. Additionally, a hand review of bibliographic references was also performed. Published works between the years of 1990 and 2017 were accepted. Cases in which the patient had previously known SLE or had coronary artery disease leading to heart failure were excluded due to the known prevalence of cardiac involvement in SLE, and the impossibility to exclude an abundance of confounding factors on literature review which could alter interpretation of index of suspicion, diagnosis, and therapeutic response such as degree of cardiovascular disease and prior treatment, prior initiation of immunosuppressive therapy for SLE, the abundance of other clinical manifestations of SLE resulting in end-organ cardiac damage, and lack of measure of cardiac-specific response to therapy.

A total of 11 cases qualifying as SLE debut with heart failure were identified as case reports and case series (Table 2) [10–19]. One case report was excluded due to insufficient information [18]. The average age at diagnosis was 31 years old (range 19–42), and females represented 80% of cases. Common throughout these cases, dyspnea was the most frequent presenting clinical manifestation. Cardiomegaly and markedly decreased left ventricular ejection fractions were described in all cases. However, only four cases were identified in which dilated cardiomyopathy was the only initial manifestation of SLE at the time of presentation, as it was in the aforementioned case.

3.1. Differential Diagnosis Considerations. In the context of acute decompensated heart failure, we found that several patients had a protracted course of progressive decompensation, with 3 patients in our retrospective analysis having multiple admissions prior to diagnosis. This echoes findings of the case series performed by Law et al., in which the median time of diagnosis of acute lupus myocarditis from symptom onset was two weeks [20]. Diagnosis was made on serologic basis in all but one case, in which lupus nephritis confirmed on biopsy was the defining factor [15]. This tendency of delayed diagnosis can occur even when connective tissue immunologic profiles are suggestive of an autoimmune etiology to heart failure, as was evidenced in the case series at tertiary care centers described by Tomas et al. [21].

3.2. Treatment and Outcomes. All cases reported use of glucocorticoid therapy for immunosuppression, while limited cases added a second immunosuppressive agent, and plasmapheresis was used in one case. All cases in our analysis in which glucocorticoid monotherapy was used resulted in functional recovery, while those adding a second drug or filtration therapy were associated with multiple admissions and a more protracted clinical course in presumably more serious cases. A clinical-functional recovery (CFR), defined as recovery of myocardial function by ECHO or clinical status back to or near previously known functional status, was reported in 90% of cases. The aggressive initiation of immunosuppressive therapy is supported by findings in echocardiography [22] and clinically [20, 21].

4. Discussion

The acute presentation of heart failure with DCM in a patient without any of the classic cardiovascular risk factors presents both a medical urgency and a diagnostic challenge. While acute coronary syndrome and pulmonary embolism must initially and quickly be ruled out, a systematic approach provides the building blocks to consider the myriad of possibilities, correctly diagnose, and thereby treat each patient. This includes consideration the less-frequent malignant, autoimmune, and infectious potential causes of disease. This case describing an African-American female whose presentation of SLE was manifested by severe myocarditis and demonstrated a paucity of other clinical findings exemplifies this clinical dilemma.

In the differential considerations of a patient with decompensated heart failure without typical cardiovascular risk factors, we find that, despite several cases being reported, heart failure as the initial manifestation of SLE remains exceedingly rare in the literature, as was observed in a large lupus cohort in Toronto over a period of more than 40 years. Acute lupus myocarditis as the presenting symptom of SLE remains a rare entity, with only 0.37% of patients presenting as such [23]. Due to lack of evidence-based consensus or a comprehensive review of the same, heart failure due to SLE continues to be an underrecognized phenomenon, thereby significantly delaying diagnosis and initiation of treatment.

Within the limited evidence and experience of therapeutic approaches, the efficacy of different singular or combined therapy is also based solely on anecdotal case reports. In compiling and comparing the therapeutic approaches of similar case reports and series in which SLE was found to be the underlying etiology of overt heart failure, we have been able to draw the following conclusions.

Given the near-universal response to a short course of high-dose steroid therapy as much in the clinical recovery as in the described recovery of myocardial function and resolution of DCM, the limited evidence based on review of these observational case studies and series supports the initial use of high-dose steroid therapy in acute lupus myocarditis.

While aggressive immunosuppression is necessary, the poly-pharmaceutical approach is not without risk and the
### Table 2: Literature review of 9 case reports and one case series reporting heart failure as the presenting sign of systemic lupus erythematosus.

| Case report | Gender | Age | Pertinent history | Signs & symptoms at presentation | Other manifestations of autoimmune disease | Diagnostic studies and workup | Treatment | Outcome | Clinical | ECHO (EP%) |
|-------------|--------|-----|-------------------|----------------------------------|---------------------------------------------|-------------------------------------|----------|---------|----------|------------|
| Ashrafi, 2011 | M 35 | None | 3 months progressive SOB, lower edema swelling | Myositis | DCM | NSR with nonsustained VT | Anti-Ro, anti-La, ANA (1:640) | Y N N Y | Worsening | Not reported |
| Baquero, 2011 | F 22 | FH: CREST | DOE, JVD, lower extremity edema | Lupus nephritis | Bilateral pleural effusions | Sinus tachycardia with nonspecific T wave changes | ESR 71, ANA (1:64), ds-DNA, anti-Smith, low C3, C4 | Y N Y N | Improved | 60% |
| Sandrasegaran, 1991 | F 42 | None | Fever x 1 week | None | Congestion, white-out | Mild ST depressions in anterior-lateral leads | Anemia, ESR 150; ANA+(1:100); lupus anticoagulant, low C3/C4, anti-Ro | Y N N N | Improved | Reported as improved; no number given |
| Frustaci, 1996 | M 38 | None | Fever, palpitations, SOB, weakness x 2 week | Mucosal ulcers | Mod pulmonary congestion | Diffuse ST-T abnormalities | Anemia, ESR 120; | Y N N N | None given | 65% |
| Routray, 2004 | F 36 | None | Dyspnea, orthopnea, tachycardia | None | Pulmonary congestion, left pleural effusion | Diffuse ST-T abnormalities | ESR 80; ANA+(1:40); anti-ds-DNA + | Y N N N | Improved | 45%, *10 day follow-up |
| Hoang, 2015 | F 26 | None | Cough, dyspnea, weight loss x 1 month | None | Bilateral lower lobe patchy infiltrates | None | Anemia, AKI, anti-Ro, | Y N N N | Improved | 60% |
| Woo, 2009 | F 27 | None | Dyspnea, orthopnea x 2 weeks | Lupus nephritis | Cardiomegaly, interstitial pulmonary edema | None | Anemia; ESR 33; ANA+; low C3/C4; ds-DNA+, anti-La | Y N N Y, 1 day | Improved | 55% |
| Uslanan, 2007 | F 32 | None | Pulitations, malaise, dyspnea, orthopnea x 10 days | Lupus nephritis, hemolysis | Cardiomegaly, pulmonary congestion bilaterally | Sinus tachycardia with nonspecific ST-T wave changes | Anemia, ESR 90, hemolysis (Coombs direct +), ANA (1:160), ds-DNA, low C3/ C4, anti-cardiolipin | Y N N Y | Improved | 55% |
| Case report | Gender | Age | Pertinent history | Signs & symptoms at presentation | Other manifestations of autoimmune disease | Diagnostic studies and workup | Treatment | Outcome |
|-------------|--------|-----|------------------|----------------------------------|------------------------------------------|---------------------------|-----------|---------|
| F 19 Arthralgias | Pancytopenia, fever | Proteinuria | Cardiomegaly, pleural effusion | None | Anemia, ANA, ds-DNA, anti-Smith, anti-cardiolipin, low C3/C4 | Hypokinesis, pericardial effusion, EF 25% | Y N Y Y | Improved |
| F 40 DVT | Dyspnea, alopecia, rash, weakness progressing to cardiogenic shock | Renal Bx lupus nephritis | Not reported | None | ANA, ds-DNA, Jo, Sm, SSA, SSB, ENA, aCL, cardiac biopsy positive | | 23 Y Y Y N | Improved 55% |

DCM: dilated cardiomyopathy; NSR: normal sinus rhythm; ECHO: transthoracic cardiac ultrasound; EF%: left ventricular ejection fraction; M: male; F: female; Y: yes; N: no; SOB: shortness of breath; DVT: deep vein thrombosis; AZA: azathioprine; CYP: cyclophosphamide; CXR: chest X-ray; Bx: biopsy; DOE: dyspnea on exertion; JVD: jugular vein distention.
addition of azathioprine and especially cyclophosphamide also adds the potential for significant myelosuppression. The limited evidence based on this literature review of case reports suggests that high-dose steroids offer a reasonable option as a first line of therapy. However, further study with respect to determining the safest and most efficacious approach to acutely heart failure due to lupus dilated cardiomyopathy is required.

5. Conclusion
Acute lupus myocarditis is a rare initial manifestation of SLE and an underappreciated cause of acute heart failure due to dilated cardiomyopathy. Limited evidence supports initial and early management with high-dose glucocorticoid therapy, with the majority of patients obtaining clinical and functional recovery. Future investigation with standardized evaluation criteria, treatment regimens, and follow-up is needed to further the management and patient outcomes of dilated cardiomyopathy secondary to lupus.

Conflicts of Interest
The authors have no potential conflicts of interest to declare with respect to the research, authorship, and publication of this article.

References
[1] M. Gheorghiade, F. Zannad, G. Sopko et al., “Acute heart failure syndromes,” Circulation, vol. 112, no. 25, pp. 3958–3968, 2005.
[2] N.-C. Vu Lam, M. V. Ghetu, and M. L. Bieniek, “Systemic lupus erythematosus: primary care approach to diagnosis and management,” American Family Physician, vol. 94, pp. 284–294, 2016.
[3] G. C. Tsokos, “Systemic lupus erythematosus,” New England Journal of Medicine, vol. 365, no. 22, pp. 2110–2121, 2011.
[4] D. P. D’Cruz, M. A. Khamashta, and G. R. Hughes, “Systemic lupus erythematosus,” The Lancet, vol. 369, no. 9561, pp. 587–596, 2007.
[5] A. Tincani, C. B. Rebiai, M. Taglietti, and Y. Shoenfeld, “Heart involvement in systemic lupus erythematosus, antiphospholipid syndrome and neonatal lupus,” Rheumatology, vol. 45, no. 4, pp. iv8–iv13, 2006.
[6] S. Appenzeller, C. Pineau, and A. Clarke, “Acute lupus myocarditis: clinical features and outcome,” Lupus, vol. 20, no. 9, pp. 981–988, 2011.
[7] M. Wijetunga and S. Rockson, “Myocarditis in systemic lupus erythematosus,” American Journal of Medicine, vol. 113, no. 5, pp. 419–423, 2002.
[8] I. Moysakis, M. G. Tektonidou, V. A. Vasiliou, M. Samarkos, V. Votteas, and H. M. Moutsopoulos, “Libman-sacks endocarditis in systemic lupus erythematosus: prevalence, associations, and evolution,” American Journal of Medicine, vol. 120, no. 7, pp. 636–642, 2007.
[9] A. L. Nightingale, J. E. Davidson, C. T. Molta, H. J. Kan, and N. J. McHugh, “Presentation of SLE in UK primary care using the clinical practice research datalink,” Lupus Science & Medicine, vol. 4, no. 1, article e000172, 2017.
[10] R. Ashrafi, P. Garg, E. McKay, J. Gosney, S. Chuah, and G. Davis, “Aggressive cardiac involvement in systemic lupus erythematosus: a case report and a comprehensive literature review,” Cardiology Research and Practice, vol. 2011, Article ID 578390, 6 pages, 2011.
[11] G. Baquero, J. E. Banchs, G. V. Naccarelli, M. Gonzalez, and D. L. Wolbrette, “Cardiogenic shock as the initial presentation of systemic lupus erythematosus: a case report and review of the literature,” Congestive Heart Failure, vol. 18, no. 6, pp. 337–341, 2012.
[12] K. Sandrasegaran, C. W. Clarke, and V. Nagendran, “Subclinical systemic lupus erythematosus presenting with acute myocarditis,” Postgraduate Medical Journal, vol. 68, no. 800, pp. 475–478, 1992.
[13] A. Frustaci, N. Gentiloni, and M. Caldarulo, “Acute myocarditis and left ventricular aneurysm as presentations of systemic lupus erythematosus,” Chests, vol. 109, no. 1, pp. 282–284, 1996.
[14] S. N. Routray, T. K. Mishra, U. K. Patnaik, and M. Behera, “Myocarditis as an initial manifestation of systemic lupus erythematosus,” Journal of the Association of Physicians of India, vol. 52, pp. 673–674, 2004.
[15] V. Hoang, D. Addison, N. Lakkis, and R. Tabbaa, “ANA-negative lupus presenting with heart failure and severe valvular dysfunction: case report and review of the literature,” Methodist DeBakey Cardiovascular Journal, vol. 11, no. 3, pp. 186–188, 2015.
[16] S.-I. Woo, G.-S. Hwang, S.-J. Kang et al., “Lupus myocarditis presenting as acute congestive heart failure: a case report,” Journal of Korean Medical Science, vol. 24, no. 1, pp. 176–178, 2009.
[17] N. E. van der Laan-Baalbergen, S. A. Mollema, H. Kritikos et al., “Heart failure as presenting manifestation of cardiac involvement in systemic lupus erythematosus,” Netherlands Journal of Medicine, vol. 67, no. 9, pp. 295–301, 2009, http://www.ncbi.nlm.nih.gov/pubmed/19841486.
[18] S. M. Cheng, D. M. Chang, W. H. Lee, and Y. A. Ding, “Acute myocarditis as an initial manifestation of systemic lupus erythematosus: a case report,” Zhonghua Yi Xue Za Zhi (Taipei), vol. 58, no. 3, pp. 205–208, 1996, http://www.ncbi.nlm.nih.gov/pubmed/8940793.
[19] C. Usalan, H. Buyukhatipoglu, and O. Tiryaki, “Systemic lupus erythematosus complicated by dilated cardiomyopathy and severe heart failure,” Clinical Rheumatology, vol. 26, no. 1, pp. 125–127, 2007.
[20] W. G. Law, B. Y. Thong, T. Y. Lian, K. O. Kong, and H. H. Chng, “Acute lupus myocarditis: clinical features and outcome of an oriental case series,” Lupus, vol. 14, no. 10, pp. 827–831, 2005.
[21] G. Thomas, F. Cohen Aubart, L. Chiche et al., “Lupus myocarditis: initial presentation and long term outcomes in a multicentric series of 29 patients,” Journal of Rheumatology, vol. 44, no. 1, pp. 24–32, 2017.
[22] G. M. Zawadowski, K. W. Klarich, K. G. Moder, W. D. Edwards, and L. T. Cooper, “A contemporary case series of lupus myocarditis,” Lupus, vol. 21, no. 13, pp. 1378–1384, 2012.
[23] J. Tanwani, K. Tselios, D. D. Gladman, J. Su, and M. B. Urowitz, “Lupus myocarditis: a single center experience and a comparative analysis of observational cohort studies,” Lupus, vol. 27, no. 8, pp. 1296–1302, 2018.